Conforming entries substitute the disorder-specific IL-6 source at the trigger node and keep the rest of the chain: lymph node stromal and plasma cells in idiopathic multicentric Castleman disease, lytically infected plasmablasts producing a viral IL-6 homolog in HHV-8-associated multicentric Castleman disease, synovial fibroblasts and macrophages in rheumatoid arthritis, activated macrophages in Still disease and in cytokine release syndrome, and tumour or stromal cells in IL-6-driven malignancy. The clinical read-out set at the consequence node is likewise substituted.
Relationship to `cytokine_storm_hyperinflammation`, which also has IL-6 at its centre: that module models the *generation* of an acute, life-threatening storm - an overwhelming immune trigger driving a self-amplifying myeloid cytokine loop, ending in endothelial capillary leak, shock and multiorgan dysfunction. This module picks up at the cytokine and models how the IL-6 *signal is transduced* and which tissue programs it turns on: gp130 engagement, JAK-STAT3, hepatic acute-phase reprogramming and B-lineage differentiation. The two therefore overlap at the IL-6 node and diverge on either side of it. Use the storm module for a disorder whose defining course is acute hyperinflammation ending in shock; use this one for a disorder whose IL-6 output drives chronic acute-phase and plasma-cell programs, which is the case for the indolent Castleman subtypes where shock never occurs. A single node conforms to one or the other, since `conforms_to` is single-valued; a disorder that does both - iMCD-TAFRO - conforms its capillary-leak node to the storm module and its cytokine chain here.
This module is deliberately distinct from `jak_stat_pathway_activation`, and a node should not conform to both. That module covers cell-intrinsic, constitutive, ligand-INDEPENDENT activation from an activating lesion in a receptor, JAK or STAT - or from lost SOCS feedback - and terminates in cytokine-independent proliferation. This module covers the opposite case: a structurally normal pathway driven by an excess of ligand, where removing the ligand or blocking its receptor switches the pathway off. A disorder in which IL-6 blockade produces clinical remission conforms here, not there.
This is not an Xogenesis module: the terminal output is a systemic physiological state, not a pathological material anatomical entity, so no MPATH/OGMS anchor stanza applies.
Sustained Interleukin-6 Oversupply
trigger
IL-6 is produced in excess of what its clearance and negative-feedback machinery can absorb, and the excess is sustained rather than transient. The producing cell is the disorder-specific substitution and varies widely - stromal cells, plasma cells, macrophages, endothelium, synovial fibroblasts, tumour cells - and in one case the ligand is not host IL-6 at all but a virally encoded homolog. Normal control operates through induction of suppressor molecules after pathway activation and through circulating soluble IL-6 receptor and gp130; sustained oversupply overwhelms it.
Downstream
-
gp130 Receptor Complex Engagement
Excess ligand drives assembly of the signaling complex; this is the step that anti-IL-6 antibody therapy removes.
Show evidence (2 references)
"Vice versa, an overproduction of IL-6 and dysregulation of the IL-6 signaling pathways can result in inflammatory and autoimmune disorders as well as cancer development suggesting that IL-6 plays a significant role in the human cytokine network."
States that overproduction of IL-6, rather than a receptor or kinase lesion, is what produces the disease states this module covers.
"The control of IL-6 signaling is regulated through the induction of suppressor molecules after activation of the IL-6 pathways as well as through the presence of sIL-6R and gp130 forms in the blood."
Describes the negative-feedback machinery that sustained oversupply overwhelms.
gp130 Receptor Complex Engagement
amplifier
IL-6 signals through a complex of IL-6, an IL-6 receptor and the signal-transducing subunit gp130. Three modes exist: classic signaling through the membrane-bound receptor, trans-signaling through a soluble receptor, and trans-presentation from a neighbouring cell. The amplification that makes hypercytokinemia systemic is trans-signaling: only a few cell types express the membrane receptor, whereas gp130 is ubiquitous, so a soluble-receptor complex dramatically enlarges the spectrum of responder cells. Pro-inflammatory responses are attributed rather to trans-signaling and regenerative or anti-inflammatory responses to classic signaling.
Downstream
-
JAK-STAT3 Activation in Responder Cells
Complex assembly dimerizes gp130 and activates the associated kinases; this is the step that anti-IL-6-receptor antibody therapy removes.
Show evidence (4 references)
"Interestingly, only few cells express membrane bound interleukin-6 receptor whereas all cells display gp130 on the cell surface."
Establishes the asymmetry between restricted receptor expression and ubiquitous gp130 that makes trans-signaling the amplifying step.
"Therefore, the generation of soluble form of the interleukin-6 receptor dramatically enlarges the spectrum of interleukin-6 target cells. This process has been named trans-signaling."
Names and defines the amplification mechanism recorded at this node.
"It turns out that regenerative or anti-inflammatory activities of interleukin-6 are mediated by classic signaling whereas pro-inflammatory responses of interleukin-6 are rather mediated by trans-signaling."
Assigns the pro-inflammatory output this module models to the trans-signaling mode specifically.
+ 1 more reference
JAK-STAT3 Activation in Responder Cells
central effector
The rate-limiting, disorder-agnostic step and the key conformance target. gp130 dimerization activates Janus kinases, which phosphorylate tyrosine residues in the gp130 cytoplasmic tail. Two arms follow: recruitment and phosphorylation of STAT transcription factors, which dimerize, translocate to the nucleus and activate target genes; and engagement of SHP-2 with activation of the Ras/Raf/MAPK pathway. Every conforming disorder funnels through this node regardless of what supplies the ligand, and it is the point a JAK inhibitor acts on.
Downstream
-
Hepatic Acute-Phase Reprogramming
-
B-Lineage Differentiation and Immunoglobulin Output
Via IL-21 from CD4+ T cells, which is the demonstrated intermediate between the IL-6 signal and B cell antibody output.
Show evidence (3 references)
"Gp130 dimerizes, leading to the activation of Janus kinases and subsequent phosphorylation of tyrosine residues within the cytoplasmic portion of gp130."
The receptor-to-kinase step this node records.
"In addition, signal transducer and activator of transcription factors are recruited, which are phosphorylated, and consequently dimerize whereupon they translocate into the nucleus and activate target genes."
The STAT arm of this node.
"This leads to the engagement of phosphatase Src homology domains containing tyrosin phosphatase-2 (SHP-2) and activation of the ras/raf/Mitogen-activated protein (MAP) kinase (MAPK) pathway."
The MAPK arm of this node.
Hepatic Acute-Phase Reprogramming
effector
STAT3-driven transcription in the hepatocyte induces the positive acute-phase proteins, including C-reactive protein and fibrinogen, while suppressing albumin synthesis; hepcidin induction restricts iron availability and produces the anemia of inflammation. These outputs reverse on IL-6 blockade, and their laboratory markers normalize in a reproducible sequence, which is the evidence that they are downstream of the cytokine rather than independent.
Downstream
-
Systemic Inflammatory Syndrome
Show evidence (1 reference)
"the median time to normalization of abnormal laboratory tests and clinical end points occurred in the following sequence: thrombocytosis, symptomatic response, elevated C-reactive protein, hypoalbuminemia, anemia, lymph node response, hyperfibrinogenemia, and elevated immunoglobulin G"
Shows the acute-phase outputs of this node - C-reactive protein, albumin, hemoglobin, fibrinogen - reversing on IL-6 blockade.
B-Lineage Differentiation and Immunoglobulin Output
effector
IL-6 drives IL-21 production by CD4+ T cells, and STAT3 in the B cell is then required for optimal immunoglobulin production and for upregulation of the master plasma cell factor PRDM1. The output is plasma cell differentiation and immunoglobulin secretion. This is a separate effector arm from the hepatic one: it acts on a different cell lineage through an IL-21 intermediate, and its clinical read-out (immunoglobulin) is the last to normalize on IL-6 blockade rather than among the first.
Downstream
-
Systemic Inflammatory Syndrome
Show evidence (2 references)
"In IL-21-treated B cells, signal transducer and activator of transcription (STAT)3 was required for optimal immunoglobulin production and upregulation of PR domain containing 1 (PRDM1(+)), the master plasma cell factor."
Establishes the STAT3 requirement for the plasma cell differentiation of this node.
"We show here that IL-21 was required for the induction of Ab production by IL-6."
Places IL-21 as the intermediate between IL-6 and antibody output.
Systemic Inflammatory Syndrome
consequence
The clinical state: fever, fatigue and weight loss, anemia of inflammation, hypoalbuminemia with third-space fluid accumulation, a raised C-reactive protein and erythrocyte sedimentation rate, hypergammaglobulinemia, and platelet counts driven away from normal. Which of these dominate is the disorder-specific substitution. The defining property for conformance is that the syndrome remits when the IL-6 axis is blocked - if it does not, the disorder is being driven by something this module does not model.
Show evidence (1 reference)
"Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 34·0%, 95% CI 11·1-54·8, p=0·0012)."
Randomised placebo-controlled evidence that this syndrome is IL-6-dependent and reversible - and, at 34%, that not every clinically similar case is.
Anti-IL-6 Monoclonal Antibody
Platform:
Monoclonal antibody
Neutralizes the cytokine itself before it can assemble a receptor complex. Siltuximab is the worked example and is approved for idiopathic multicentric Castleman disease.
Evidence: 1
Anti-IL-6-Receptor Monoclonal Antibody
Platform:
Monoclonal antibody
Blocks the receptor rather than the ligand. Tocilizumab is the worked example and is approved for rheumatoid arthritis, cytokine release syndrome and idiopathic multicentric Castleman disease - three disorders that conform to this module by different triggers.
Evidence: 1
JAK Inhibition
Platform:
Small molecule
Acts inside the responder cell at the central effector node, downstream of both the cytokine and its receptor. This is the rational option when the ligand is not host IL-6 or when more than one gp130-family cytokine is contributing, since it does not depend on neutralizing a single ligand.
Evidence: 1